Analystreport

Adaptimmune Therapeutics (NASDAQ: ADAP) had its "buy" rating re-affirmed by analysts at Raymond James. They now have a $20.00 price target on the stock.

Adaptimmune Therapeutics plc - American Depositary Shares  (ADAP) 
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am Check Earnings Report